CRISPR Therapeutics AG (CRSP) Financial Statements
CRISPR Therapeutics AG (CRSP) reported trailing twelve-month revenue of $13.4M (down 64.8% year on year) and net income of -$451.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$371.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRSPCRISPR Therapeutics AGFollow CRSP — free
—
Price chart with a free account
- Market cap
- 4.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.01 | 0.04 | 0.00 | 0.29 | 0.00 | 0.91 | 0.00 | 0.37 | 0.04 | 0.00 | 0.01 | |
| Gross profit | — | — | — | — | — | 0.81 | — | 0.24 | — | — | — | |
| Research & development | 0.04 | 0.07 | 0.11 | 0.18 | 0.22 | 0.34 | 0.46 | 0.39 | 0.31 | 0.28 | 0.28 | |
| Operating income | -0.07 | -0.06 | -0.16 | 0.05 | -0.35 | 0.37 | -0.67 | -0.22 | -0.47 | -0.66 | -0.53 | |
| Pre-tax income | -0.02 | -0.07 | -0.16 | 0.07 | -0.35 | 0.38 | -0.65 | -0.15 | -0.36 | -0.58 | -0.45 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -0.02 | -0.07 | -0.16 | 0.07 | -0.35 | 0.38 | -0.65 | -0.15 | -0.37 | -0.58 | -0.45 | |
| Diluted EPS ($) | -1.89 | -1.71 | -3.44 | 1.17 | -5.29 | 4.70 | -8.36 | -1.94 | -4.34 | -6.47 | -4.74 | |
| Diluted shares (bn) | — | — | — | 0.057 | 0.066 | 0.080 | 0.078 | 0.079 | 0.084 | 0.090 | — |
USD billions · SEC XBRL
CRISPR Therapeutics AG — questions
- What is CRISPR Therapeutics AG's revenue?
- $13.4M over the twelve months to 2026-06-30, down 64.8% year on year, from its 10-Q and 10-K filings.
- What is CRISPR Therapeutics AG's net income?
- -$451.1M over the twelve months to 2026-06-30.
- What is CRISPR Therapeutics AG's free cash flow?
- -$371.3M over the twelve months to 2026-06-30.
- What are CRISPR Therapeutics AG's diluted earnings per share?
- $-4.74 over the twelve months to 2026-06-30.
Every figure on this page comes from CRISPR Therapeutics AG's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.